Elkedonia secures EUR 11.25 million in Seed funding to launch innovative neuroplastogens aimed at treating depression and neuropsychiatric disorders.

Target Information

Elkedonia SAS, a pioneering startup focused on developing innovative neuroplastogens, has successfully closed a EUR 11.25 million Seed funding round to advance its promise as a therapeutic agent for depression and neuropsychiatric disorders. The startup integrates cutting-edge research from Sorbonne University and leverages the expertise of the international startup studio Argobio. Elkedonia's unique molecules are designed to target non-synaptic pathways, distinguishing them from conventional treatments like ketamine.

Founded by Argobio, Elkedonia's research is led by Dr. Jocelyne Caboche, a prominent figure in neuroplasticity studies at CNRS, Sorbonne University. Their central focus is on the Elk1 protein, a crucial element affecting reward brain circuits and neuroplasticity, particularly in conditions such as depression, PTSD, and addiction.

Industry Overview

The global prevalence of Major Depressive Disorder (MDD) highlights a severe mental health crisis, affecting approximately 300 million people worldwide. Despite the extensive marketing of anti-depressant therapeutics, many patients, specifically